Thursday’s Big Movers (RBN, RDEN, MDRX, JRCC, PSTI)

U.S stocks ended slightly lower on Thursday, halting its 4-day rally with the S&P 500 index continuing its winning streak into a fifth session, its longest since the middle of March. The market has been "drifiting up while everyone is at the beach," Randy Warren, chief investment officer at Warren Financial Service in Exton, Penn., said of the market's recent steady climb.

Robbins & Myers Inc (NYSE:RBN) jumped up 27.41% to $59.63. Robbins & Myers Inc and National Oilwell Varco Inc have entered into an agreement under which National Oilwell Varco will acquire Robbins & Myers for a deal value approximately $2.5 billion. Under the agreement, Robbins & Myers' shareholders will receive $60.00 per share in cash in return.

Elizabeth Arden Inc (NASDAQ:RDEN) soared 12.99% to $44.02 on Thursday. The Company reported fourth quarter profit of $3.6 million or 12 cents per share compared to $5.4 million or 18 cents per share in the prior year period. The decline in profit was due to beauty products Company booked charges for transition expenses and other costs tied to a fragrance license acquisition. However, analysts forecast earnings of 20 cents. Sales jumped 4.6% to $265.5 million. Gross margin was 48.8% from 47.4% and operating expenses climbed 9.1% to $120.8 million.

Should Investors Buy RDEN Now? Get Free Trend Analysis

Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) was among the gainers and the stock moved up 18.44% to $11.37 after the Company announced second quarter results.  Revenue was $370 million versus $356.8 million in the prior year period. However, analysts expected revenues of $369.98 million for the quarter. Bookings for the quarter declined to $194.1 million from $244.6 million last year. Total cost of revenues increased to $212.5 million from $189 million last year. Profit was $8 million or $0.04 per share compared to $15.9 million or $0.08 per share in the prior year period.

How Should Investors Trade MDRX Now, Find Here

James River Coal Company (NASDAQ:JRCC) surged up 13% to $2.52. The Company posted second quarter net loss of $25.8 million or $0.74 per diluted share compared to net income of $0.8 million or $0.02 per diluted share in the second quarter of 2011. 

Pluristem Therapeutics Inc (NASDAQ:PSTI) increased 13.76% to $4.05. The Company has received approval from the Paul-Ehrlich-Institute to commence a Phase I/II randomized, double blind, placebo controlled study to assess the safety and efficacy of its PLX cells, through intramuscular injections, for the regeneration of injured gluteal musculature following total hip replacement. Paul-Ehrlich-Institute is the medical regulatory body in Germany.

Get Free Trend Analysis on PSTI